Top

Published in:

Open Access 01-02-2018 | Invited Review

Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature

Authors: Andrea Mari, Riccardo Campi, Riccardo Tellini, Giorgio Gandaglia, Simone Albisinni, Mohammad Abufaraj, Georgios Hatzichristodoulou, Francesco Montorsi, Roland van Velthoven, Marco Carini, Andrea Minervini, Shahrokh F. Shariat

Published in: World Journal of Urology | Issue 2/2018

Abstract

Purpose

To review the currently available literature reporting the patterns of recurrence and their predictive factors after open radical cystectomy (RC) for bladder cancer.

Methods

A review of the literature was performed using the MEDLINE, Scopus and Web of Sciences databases from January 1997 to May 2017. The PRISMA guidelines were followed for the conduct of the study.

Results

Local recurrence rate ranges between 30 and 54%. Distant recurrence is not often standardized and is reported in up to 50% of cases. The overall 5-year recurrence-free survival rates from 58 to 81%. The mean follow-up of studies included in the analysis ranged from 18 to 350 months. Details on the most important demographic and epidemiological, clinical, histologic and pathologic predictors of recurrence after radical cystectomy are provided through an evidence-based approach. The impact of the extension of lymph node dissection on recurrence after RC is investigated.

Conclusions

A correct prognostic assessment is essential for patients undergoing radical cystectomy for bladder cancer, thereby potentially improving their oncologic outcomes.

Available only for authorised users

Alfred Witjes J, Lebret T, Comperat EM et al (2016) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. https://doi.org/10.1016/j.eururo.2016.06.020

Chromecki TF, Cha EK, Fajkovic H et al (2013) Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int 111:249–255. https://doi.org/10.1111/j.1464-410X.2012.11322.x CrossRefPubMed

Xylinas E, Cha EK, Sun M et al (2012) Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer 107:1826–1832. https://doi.org/10.1038/bjc.2012.464 CrossRefPubMedPubMedCentral

Zehnder P, Studer UE, Skinner EC et al (2013) Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int 112:E51–E58. https://doi.org/10.1111/bju.12215 CrossRefPubMed

Roupret M, Drouin SJ, Larre S et al (2011) Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol 18:3833–3838. https://doi.org/10.1245/s10434-011-1824-y CrossRefPubMed

Deeks JJ, Dinnes J, D’Amico R, et al (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7:iii–x, 1–173

Griffiths G, Hall R, Sylvester R et al (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177. https://doi.org/10.1200/JCO.2010.32.3139 CrossRefPubMed

Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866. https://doi.org/10.1056/NEJMoa022148 CrossRefPubMed

Tracey E, Roder D, Luke C, Bishop J (2009) Bladder cancer survivals in New South Wales, Australia: why do women have poorer survival than men? BJU Int 104:498–504. https://doi.org/10.1111/j.1464-410X.2009.08527.x CrossRefPubMed

10.

Mungan NA, Kiemeney LA, van Dijck JA et al (2000) Gender differences in stage distribution of bladder cancer. Urology 55:368–371CrossRefPubMed

11.

Messer JC, Shariat SF, Dinney CP et al (2014) Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 83:863–867. https://doi.org/10.1016/j.urology.2013.10.060 CrossRefPubMed

12.

Mitra AP, Skinner EC, Schuckman AK et al (2014) Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1994 patients. Urol Oncol Semin Orig Invest 32:52.e1–52.e9. https://doi.org/10.1016/j.urolonc.2013.08.007

13.

Abdollah F, Sun M, Schmitges J et al (2012) Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study. Ann Surg Oncol 19:309–317. https://doi.org/10.1245/s10434-011-1852-7 CrossRefPubMed

14.

Horovitz D, Turker P, Bostrom PJ et al (2012) Does patient age affect survival after radical cystectomy? BJU Int 110:E486–E493. https://doi.org/10.1111/j.1464-410X.2012.11180.x CrossRefPubMed

15.

Nielsen ME, Shariat SF, Karakiewicz PI et al (2007) Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 51:698–699. https://doi.org/10.1016/j.eururo.2006.11.004 CrossRef

16.

Rink M, Zabor EC, Furberg H et al (2013) Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol 64:456–464. https://doi.org/10.1016/j.eururo.2012.11.039 CrossRefPubMed

17.

Bostrom PJ, Alkhateeb S, Trottier G et al (2012) Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. BJU Int 109:70–76. https://doi.org/10.1111/j.1464-410X.2011.10371.x CrossRefPubMed

18.

Lee C, Kim KH, You D et al (2012) Smoking and survival after radical cystectomy for bladder cancer. Urology 80:1307–1312. https://doi.org/10.1016/j.urology.2012.08.026 CrossRefPubMed

19.

D’Andrea D, Moschini M, Gust KM et al (2017) Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. J Surg Oncol 115:455–461. https://doi.org/10.1002/jso.24521 CrossRefPubMed

20.

Viers BR, Boorjian SA, Frank I et al (2014) Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol 66:1157–1164. https://doi.org/10.1016/j.eururo.2014.02.042 CrossRefPubMed

21.

Temraz S, Mukherji D, Farhat ZAA et al (2014) Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis. BMC Urol 14:76. https://doi.org/10.1186/1471-2490-14-76 CrossRefPubMedPubMedCentral

22.

Djaladat H, Bruins HM, Miranda G et al (2014) The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer. BJU Int 113:887–893. https://doi.org/10.1111/bju.12240 CrossRefPubMed

23.

Liu J, Dai Y, Zhou F et al (2016) The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. Urol Oncol 34:484.e1–484.e8. https://doi.org/10.1016/j.urolonc.2016.05.024 CrossRef

24.

Moschini M, Suardi N, Pellucchi F et al (2014) Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. Anticancer Res 34:3225–3230PubMed

25.

Xia L, Guzzo TJ (2017) Preoperative anemia and low hemoglobin level are associated with worse clinical outcomes in patients with bladder cancer undergoing radical cystectomy: a meta-analysis. Clin Genitourin Cancer 15(263–272):e4. https://doi.org/10.1016/j.clgc.2016.08.017

26.

Engel O, Soave A, Peine S et al (2015) The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. World J Urol 33:1769–1776. https://doi.org/10.1007/s00345-015-1531-6 CrossRefPubMed

27.

Miyake M, Morizawa Y, Hori S et al (2017) Integrative assessment of pretreatment inflammation-, nutrition-, and muscle-based prognostic markers in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Oncology 93:259–269. https://doi.org/10.1159/000477405 CrossRefPubMed

28.

Koppie TM, Serio AM, Vickers AJ et al (2008) Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 112:2384–2392. https://doi.org/10.1002/cncr.23462 CrossRefPubMed

29.

Moschini M, Shariat SF, Abufaraj M et al (2017) The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. Urol Oncol 35:151.e17–151.e23. https://doi.org/10.1016/j.urolonc.2016.11.003 CrossRef

30.

Mayr R, May M, Burger M et al (2014) The Charlson comorbidity index predicts survival after disease recurrence in patients following radical cystectomy for urothelial carcinoma of the bladder. Urol Int 93:303–310. https://doi.org/10.1159/000362421 CrossRefPubMed

31.

Dabi Y, Rouscoff Y, Anract J et al (2017) Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer. World J Urol 35:229–235. https://doi.org/10.1007/s00345-016-1852-0 CrossRefPubMed

32.

Rieken M, Xylinas E, Kluth L et al (2014) Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol Oncol 32:49.e7–14. https://doi.org/10.1016/j.urolonc.2013.07.006 CrossRefPubMed

33.

Milowsky MI, Rumble RB, Booth CM et al (2016) Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol 34:1945–1952. https://doi.org/10.1200/JCO.2015.65.9797 CrossRefPubMed

34.

Hollenbeck BK, Miller DC, Dunn RL et al (2005) The effects of stage divergence on survival after radical cystectomy for urothelial cancer. Urol Oncol 23:77–81. https://doi.org/10.1016/j.urolonc.2004.08.012 CrossRefPubMed

35.

Culp SH, Dickstein RJ, Grossman HB et al (2014) Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 191:40–47. https://doi.org/10.1016/j.juro.2013.07.061 CrossRefPubMed

36.

Moschini M, Soria F, Klatte T et al (2017) Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy. Clin Genitourin Cancer 15:e267–e273. https://doi.org/10.1016/j.clgc.2016.07.014 CrossRefPubMed

37.

Lotan Y, Gupta A, Shariat SF et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23:6533–6539. https://doi.org/10.1200/JCO.2005.05.516 CrossRefPubMed

38.

Xylinas E, Rink M, Robinson BD et al (2013) Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 49:1889–1897. https://doi.org/10.1016/j.ejca.2013.02.001 CrossRefPubMed

39.

Soave A, Schmidt S, Dahlem R et al (2015) Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? Urol Oncol 33:21.e1–9. https://doi.org/10.1016/j.urolonc.2014.10.013 CrossRef

40.

Fairey AS, Daneshmand S, Wang L et al (2014) Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. Urol Oncol 32:110–116. https://doi.org/10.1016/j.urolonc.2012.04.020 CrossRefPubMed

41.

Moschini M, Shariat SF, Luciano R et al (2016) Pure but not mixed histologic variants are associated with poor survival at radical cystectomy in bladder cancer patients. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2016.12.006

42.

Zargar-Shoshtari K, Sverrisson EF, Sharma P et al (2016) Clinical outcomes after neoadjuvant chemotherapy and radical cystectomy in the presence of urothelial carcinoma of the bladder with squamous or glandular differentiation. Clin Genitourin Cancer 14:82–88. https://doi.org/10.1016/j.clgc.2015.08.006 CrossRefPubMed

43.

Shariat SF, Palapattu GS, Amiel GE et al (2006) Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology 68:538–542. https://doi.org/10.1016/j.urology.2006.03.033 CrossRefPubMed

44.

Shariat SF, Palapattu GS, Karakiewicz PI et al (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51:152–160. https://doi.org/10.1016/j.eururo.2006.08.037 CrossRefPubMed

45.

Wheat JC, Weizer AZ, Wolf JSJ et al (2012) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol Oncol 30:252–258. https://doi.org/10.1016/j.urolonc.2010.01.001 CrossRefPubMed

46.

Nuhn P, Bastian PJ, Novara G et al (2011) Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int 87:42–48. https://doi.org/10.1159/000325463 CrossRefPubMed

47.

Yafi FA, Aprikian AG, Chin JL et al (2014) Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World J Urol 32:1295–1301. https://doi.org/10.1007/s00345-013-1207-z CrossRefPubMed

48.

Herr H, Lee C, Chang S, Lerner S (2004) Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol 171:1823–1828. https://doi.org/10.1097/01.ju.0000120289.78049.0e CrossRefPubMed

49.

Dotan ZA, Kavanagh K, Yossepowitch O et al (2007) Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol 178:2308–2313. https://doi.org/10.1016/j.juro.2007.08.023 CrossRefPubMed

50.

Neuzillet Y, Soulie M, Larre S et al (2013) Positive surgical margins and their locations in specimens are adverse prognosis features after radical cystectomy in non-metastatic carcinoma invading bladder muscle: results from a nationwide case–control study. BJU Int 111:1253–1260. https://doi.org/10.1111/j.1464-410X.2012.11664.x CrossRefPubMed

51.

Bochner BH, Kattan MW, Vora KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24:3967–3972. https://doi.org/10.1200/JCO.2005.05.3884 CrossRefPubMed

52.

Simone G, Bianchi M, Giannarelli D et al (2015) Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. World J Urol 33:1419–1428. https://doi.org/10.1007/s00345-014-1465-4 CrossRefPubMed

53.

Di Trapani E, Sanchez-Salas R, Gandaglia G et al (2016) A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. World J Urol 34:207–213. https://doi.org/10.1007/s00345-015-1640-2 CrossRefPubMed

54.

Umbreit EC, Crispen PL, Shimko MS et al (2010) Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma. Cancer 116:3399–3407. https://doi.org/10.1002/cncr.25202 CrossRefPubMed

55.

Bruins HM, Huang GJ, Cai J et al (2009) Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol 182:2182–2187. https://doi.org/10.1016/j.juro.2009.07.017 CrossRefPubMed

56.

Tarin TV, Power NE, Ehdaie B et al (2012) Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol 61:1025–1030. https://doi.org/10.1016/j.eururo.2012.01.049 CrossRefPubMedPubMedCentral

57.

Simone G, Papalia R, Ferriero M et al (2012) Development and external validation of lymph node density cut-off points in prospective series of radical cystectomy and pelvic lymph node dissection. Int J Urol 19:1068–1074. https://doi.org/10.1111/j.1442-2042.2012.03103.x CrossRefPubMed

58.

Abdi H, Pourmalek F, Gleave ME et al (2016) Balancing risk and benefit of extended pelvic lymph node dissection in patients undergoing radical cystectomy. World J Urol 34:41–48. https://doi.org/10.1007/s00345-015-1734-x CrossRefPubMed

59.

May M, Herrmann E, Bolenz C et al (2011) Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol 18:2018–2025. https://doi.org/10.1245/s10434-010-1538-6 CrossRefPubMed

60.

Zehnder P, Studer UE, Skinner EC et al (2011) Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 186:1261–1268. https://doi.org/10.1016/j.juro.2011.06.004 CrossRefPubMed

Title: Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature
Authors: Andrea Mari
Riccardo Campi
Riccardo Tellini
Giorgio Gandaglia
Simone Albisinni
Mohammad Abufaraj
Georgios Hatzichristodoulou
Francesco Montorsi
Roland van Velthoven
Marco Carini
Andrea Minervini
Shahrokh F. Shariat
Publication date: 01-02-2018
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 2/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-017-2115-4

At a glance: The STEP trials

Springer Medicine

Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

In vivo assessment of a novel biodegradable ureteral stent

Short-term outcome after cystectomy: comparison of early oral feeding in an enhanced recovery protocol and feeding using Bengmark nasojejunal tube

Prospective comparison among three intrarectal anesthetic treatments combined with periprostatic nerve block during transrectal ultrasonography-guided prostate biopsy

Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder

Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy

A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer